Showing results (151-160 of 531) with videos related to
Sort By:
Pageof 54
Diabetes Care|June 28, 2006
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)Robert H Knopp, Michael d'Emden, Johan G Smilde, et al.British Medical Journal (Clinical Research Ed.)|March 21, 1987
Alcohol and ischaemic heart disease in middle aged British menA G Shaper, A N Phillips, S J Pocock, et al.Gut|July 1, 1977
Variation in the incidence of diverticular disease within the city of EdinburghM A Eastwood, J Sanderson, S J Pocock, et al.Statistics in Medicine|January 10, 2002
Impact of missing data due to drop-outs on estimators for rates of change in longitudinal studies: a simulation studyG Touloumi, A G Babiker, S J Pocock, et al.Statistics in Medicine|February 15, 2003
Adjusting treatment comparisons to account for non-randomized interventions: an example from an angina trialIan R White, James Carpenter, Stuart J Pocock, et al.Epidemiology (Cambridge, Mass.)|April 20, 2002
Impact of missing data due to selective dropouts in cohort studies and clinical trialsGiota Touloumi, Stuart J Pocock, Abdel G Babiker, et al.British Medical Journal (Clinical Research Ed.)|August 23, 1986
Identifying men at high risk of heart attacks: strategy for use in general practiceA G Shaper, S J Pocock, A N Phillips, et al.Arzneimittel-Forschung|January 1, 1985
The role of immunoglobulin E receptors in allergic diseasesW König, P Pfeiffer, I Rauschen, et al.Health Trends|April 10, 1987
A scoring system to identify men at high risk of a heart attackA G Shaper, S J Pocock, A N Phillips, et al.European Heart Journal|September 9, 2011
The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical prioritiesStuart J Pocock, Cono A Ariti, Timothy J Collier, et al.Pageof 54